The agenda for the 19 November 2014 Transparency Commission meeting is now available.  The Commission will consider the following medicines:

• Teduglutide (Revestive) - new medicine
• Cabozantinib mesylate (Cometriq) - new medicines
• Yttrium Yt90 chloride (Yttriga) - new medicine
• Vernakalant (Brinavess) - new medicine

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-11/odj_ct_19112014_internet.pdf [French]